Please login to the form below

Not currently logged in
Email:
Password:

PARP inhibitor

This page shows the latest PARP inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for

Latest news

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    New R&D chief Hal Barron was also on hand to underline the clinical potential of the PARP inhibitor class, including benefitting patients with other mutations. ... The company already has Zeluja in combination trials with TSR-022, with all the

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    He also revealed that Nektar has agreed to test NKTR-214 with Pfizer’s PD-L1 inhibitor Bavencio (avelumab), PARP inhibitor talazoparib and anti-androgen drug enzalutamide in indications outside the ... Takeda is also a partner and will look at

  • First-line ovarian approval cements AZ’s Lynparza lead First-line ovarian approval cements AZ’s Lynparza lead

    Also new data on recently approved kidney disease drug. AstraZeneca’s Lynparza has become the first PARP inhibitor to be approved for first-line maintenance therapy in BRCA-mutated ovarian cancer, ... Lynparza is already well in front of its PARP

  • Analysts lukewarm on GSK’s new cancer acquisition Analysts lukewarm on GSK’s new cancer acquisition

    That includes the marketed PARP inhibitor Zejula (niraparib) that it says is in a market with “very favourable growth prospects,” albeit with strong competition from AstraZeneca and Merck/MSD’s ... Paul Jeng. Last year, Zejula became the first PARP

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... a wave of new PARP inhibitors coming through the

More from news
Approximately 1 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The PARP inhibitor drug prevents BRCA mutation-carrying cells from repairing themselves, causing them to die. ... KUDOS had discovered olaparib, the first-in- class PARP inhibitor, which Galbraith’s team developed and brought to market as Lynparza.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... 540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute

  • Deal Watch April 2016 Deal Watch April 2016

    3, 340. Nimbus Apollo (US). Gilead (US). Company acquisition. Phase I Acetyl-CoA Carboxylase (ACC) inhibitor programme for live disease. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for

  • Pharma deals in August 2015 Pharma deals in August 2015

    Looking at another combination, AstraZeneca entered into a clinical trial collaboration this time with durvalumab in combination with Mirati Therapeutics' investigational spectrum-selective histone deacetylase (HDAC) inhibitor, mocetinostat.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics